Drug Survival, Safety, and Effectiveness of Biologics in Older Patients with Psoriasis: A Comparison with Younger Patients—A BioCAPTURE Registry Study

E. L. M. ter Haar1,2, S. E. Thomas1,2, J. M. P. A. van den Reek1,2, M. E. Otero1,2, M. D. Njoo3, P. M. Ossenkoppele1, E. N. Kop4, S. R. P. Dodemont5, J. E. M. Köver6, A. L. A. Kuijpers2, R. J. Lindhout6, R. A. Tupker9, J. M. Mommers10, M. A. M. Berends11, M. I. A. Koetsier12, M. S. de Bruin-Weller13, M. B. Visch14, W. P. Arnold15, P. P. M. van Lümig16, M. M. Kleinpenning17, S. F. K. Lubeek1,2, E. M. G. J. de Jong1,2,18

Accepted: 8 June 2022 / Published online: 21 July 2022
© The Author(s) 2022

Abstract

Background Psoriasis is a common inflammatory disease in any age group, but also in older patients (≥ 65 years of age). Since older patients are often excluded from clinical trials, limited data specifically on this growing population are available, e.g. regarding the safety and performance of biological treatment.

Aims We aimed to give insight into this specific population by comparing the drug survival and safety of biologics in older patients with that in younger patients.

Methods In this real-world observational study, data from 3 academic and 15 non-academic centers in The Netherlands were extracted from the prospective BioCAPTURE registry. Biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors. Patients were divided into two age groups: ≥ 65 years and < 65 years. The Charlson Comorbidity Index (CCI) was used to measure comorbid disease status, and all adverse events (AEs) that led to treatment discontinuation were classified according to the Medical Dictionary for Regulatory Activities (MedDRA) classification. All AEs that led to treatment discontinuation were studied to check whether they could be classified as serious AEs (SAEs). Kaplan–Meier survival curves for overall 5-year drug survival and split according to reasons of discontinuation (ineffectiveness or AEs) were constructed. Cox regression models were used to correct for possible confounders and to investigate associations with drug survival in both age groups separately. Psoriasis Area and Severity Index (PASI) scores during the first 2 years of treatment and at the time of treatment discontinuation were assessed and compared between age groups.

Results A total of 890 patients were included, of whom 102 (11.4%) were aged ≥ 65 years. Body mass index, sex, and distribution of biologic classes (e.g. TNFα, IL12/23) were not significantly different between the two age groups. A significantly higher CCI score was found in older patients, indicative of more comorbidity (p < 0.001). The 5-year ineffectiveness-related drug survival was lower for older patients (44.5% vs. 60.5%; p = 0.006), and the 5-year overall (≥ 65 years: 32.4% vs. < 65 years: 42.1%; p = 0.144) and AE-related (≥ 65 years: 82.1% vs. < 65 years: 79.5%; p = 0.913) drug survival was comparable between age groups. Of all AEs (n = 155) that led to discontinuation, 16 (10.3%) were reported as SAEs but these only occurred in younger patients. After correcting for confounders, the same trends were observed in the drug survival outcomes. Linear regression analyses on PASI scores showed no statistical differences at 6, 12, 18, and 24 months of treatment between age groups.

Conclusions This study in a substantial, well-defined, prospective cohort provides further support that the use of biologics in older patients seems well-tolerated and effective. Biologic discontinuation due to AEs did not occur more frequently in older patients. Older patients discontinued biologic treatment more often due to ineffectiveness, although no clear difference in PASI scores was observed. More real-world studies on physician- and patient-related factors in older patients are warranted.

E. L. M. ter Haar and S. E. Thomas share first authorship.

Extended author information available on the last page of the article
Key Points

In this real-world observational study regarding biologic treatment for psoriasis, drug survival, effectiveness, and safety were mainly comparable between age groups (<65 years and ≥65 years).

Treatment of older patients with biologics appears a well-tolerated and effective therapeutic option.

1 Introduction

Psoriasis is a chronic immune-mediated disease associated with not only a physical but also a psychological burden. It affects 2–4% of the world’s population and can occur at any age [1]. The combination of an aging world population and the chronic course of psoriasis results in an increase in the prevalence of older patients with psoriasis [1, 2]. As older patients are often excluded from clinical trials, only limited literature for this specific population is available regarding the effectiveness and safety of systemic anti-psoriatic treatments [3–5].

Biologics are the most recent addition to the arsenal of therapeutic options for psoriasis and appear to be more effective than conventional systemic therapies in older patients [3]. However, choosing the optimal type of treatment can be challenging in older patients, not only due to limited evidence on safety and effectiveness but also due to possibly complicating patient characteristics such as comorbidities, concomitant medication use, polypharmacy, functional status, and frailty. Therefore, it is possible that physicians are reluctant to prescribe certain systemic therapies such as biologics in older patients, which could lead to undertreatment of this patient group [6].

With this prospective observational real-world study in patients using biologics for psoriasis, we aimed to provide insight into the drug survival, safety, and effectiveness of biologics in older patients and compare outcomes with a younger population.

2 Materials and Methods

2.1 The BioCAPTURE Database

In this real-world cohort study, data were extracted from the prospective, multicenter Continuous Assessment of Psoriasis Treatment Use Registry with Biologics (BioCAPTURE registry; www.biocapture.nl). We used data on psoriasis patients treated with biologic therapy from 3 academic and 15 non-academic centers in The Netherlands (2005–2021). The biologics included in this study were tumor necrosis factor (TNF)-α, interleukin (IL)-17, IL-12/23, and IL-23 inhibitors (see Table 1). According to the regional Medical Ethics Committee, ethical approval was not necessary for this non-interventional study. Nevertheless, written informed consent is obtained from every included patient.

2.2 Data Collection

Data were collected from adult patients treated with biologics. Two age groups were compared: patients ≥65 years and <65 years of age at the start of biological treatment. The 65 years of age threshold was chosen because it is widely used in psoriasis literature [3, 7, 8]. In this study, the first biologic treatment episode (TE) per patient in BioCAPTURE was included. A TE represents a continuous period of time in which a patient was treated with a certain biologic. If treatment was interrupted ≥ 90 days, the TE ended. The maximum follow-up duration was set at 5 years. Baseline patient characteristics were collected and calculated for every TE. To measure comorbid disease status, the International Classification of Diseases, Tenth Revision (ICD-10) version of the Charlson Comorbidity Index (CCI) was used [9, 10]. In addition to the CCI, depression and hypertension were added as these were regarded relevant comorbidities in the context of psoriasis. To assess the possibility that this cohort was comprised of relatively healthy older patients due to pre-selection on comorbidity in the context of biologic therapy initiation, a comparison of CCI scores with another Dutch psoriasis cohort including older adults (≥65 years) using all types of antipsoriatic therapy (n = 230) was performed (data available upon request). This study was reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) criteria [11].

2.3 Drug Survival Analysis

Drug survival up to 5 years of treatment was visualized using Kaplan–Meier survival curves. For the overall drug survival curve, discontinuation due to ineffectiveness, adverse events (AEs), ineffectiveness and AEs combined, other reasons, and death were considered an event. Additionally, we assessed drug survival according to reason for discontinuation (separately for ineffectiveness and AEs). Patients were censored when lost to follow-up, when still ‘on drug’ at the moment of data lock (with a maximum follow-up of 5 years), or when a patient reached the age of 65 years during treatment. For the analyses based on discontinuation reasons, patients were
Table 1  Patient and treatment characteristics of older patients, compared with younger patients, using biologic treatment

|                                | < 65 years of age [n = 788] | ≥ 65 years of age [n = 102] | All patients [n = 890] | p value<sup>a</sup> |
|--------------------------------|-----------------------------|-----------------------------|-------------------------|---------------------|
| Age at start of biologic treatment, years | NA                          | 45.4 ± 11.1                 | 70.3 ± 4.1              | 48.2 ± 13.2         |
|                                | Median (range)              | 45.9 (19.1–64.8)            | 69.9 (65.1–82.5)        | 48.3 (19.1–82.5)    |
| Sex [n (%)]<sup>c</sup>         |                             |                             |                         | 0.515               |
| Male                           | 487 (62.6)                  | 60 (58.8)                   | 547 (62.2)              |
| Female                         | 291 (37.4)                  | 42 (41.2)                   | 333 (37.8)              |
| Hospital type [n (%)]<sup>c</sup> |                             |                             |                         | 0.437               |
| Academic                       | 526 (66.8)                  | 64 (62.7)                   | 590 (66.3)              |
| Non-academic                   | 262 (33.2)                  | 38 (37.3)                   | 300 (33.7)              |
| Body mass index, kg/m<sup>2</sup><sup>c</sup> |                             |                             |                         | 0.930               |
| Mean ± SD                      | 28.9 ± 6.1                  | 28.5 ± 4.3                  | 28.9 ± 5.9              |
| Median (range)                 | 27.9 (16.4–69.9)            | 27.3 (21.4–42.6)            | 27.9 (16.4–69.9)        |
| Age at onset of psoriasis, years<sup>c</sup> | NA                          | 24.8 ± 12.3                 | 41.9 ± 18.8             | 26.7 ± 14.2         |
|                                | Median (range)              | 22.0 (0–59)                 | 47.0 (2–76)             | 23.0 (0–76)         |
| Duration of psoriasis until start of biologic, years<sup>b</sup><sup>c</sup> | NA                          | 20.0 ± 11.9                 | 26.5 ± 18.5             | 20.7 ± 12.9         |
|                                | Median (range)              | 18.2 (0.6–57.2)             | 17.4 (1.7–72.0)         | 18.2 (0.6–72.0)     |
| Biologic naïve [n (%)]<sup>c</sup> |                             |                             |                         | 0.827               |
| Yes                            | 510 (64.7)                  | 65 (63.7)                   | 575 (64.6)              |
| No                             | 278 (35.3)                  | 37 (36.3)                   | 315 (35.4)              |
| Family history of psoriasis [n (%)]<sup>c</sup> |                             |                             |                         | 0.311               |
| Yes                            | 472 (66.9)                  | 50 (59.5)                   | 522 (66.1)              |
| No                             | 234 (33.1)                  | 33 (40.5)                   | 268 (33.9)              |
| Psoriatic arthritis [n (%)]<sup>c</sup> |                             |                             |                         | 0.447               |
| Yes                            | 211 (32.0)                  | 22 (27.2)                   | 233 (31.5)              |
| No                             | 448 (68.0)                  | 59 (72.8)                   | 507 (68.5)              |
| Baseline PASI score<sup>c</sup> |                             |                             |                         | 0.421               |
| Mean ± SD                      | 13.2 ± 7.7                  | 12.3 ± 6.8                  | 13.1 ± 7.6              |
| Median (range)                 | 11.8 (0–45.2)               | 11.0 (0–36.2)               | 11.4 (0–45.2)           |
| Biologic treatment [n (%)]     |                             |                             |                         | 0.291               |
| TNFα                           | 515 (65.4)                  | 74 (72.5)                   | 589 (66.2)              |
| Adalimumab                     | 268 (34.0)                  | 49 (48.0)                   | 317 (35.6)              |
| Certolizumab                   | 4 (0.5)                     | 0 (0.0)                     | 4 (0.4)                 |
| Etanercept                     | 234 (29.7)                  | 25 (24.5)                   | 259 (29.1)              |
| Infliximab                     | 9 (1.1)                     | 0 (0.0)                     | 9 (1.0)                 |
| IL-12/23 (ustekinumab)         | 182 (23.1)                  | 21 (20.6)                   | 203 (22.8)              |
| IL-17                          | 60 (7.6)                    | 3 (2.9)                     | 63 (7.1)                |
| Brodalumab                     | 3 (0.4)                     | 1 (1.0)                     | 4 (0.4)                 |
| Ixekizumab                     | 23 (2.9)                    | 1 (1.0)                     | 24 (2.7)                |
| Secukinumab                    | 34 (4.3)                    | 1 (1.0)                     | 35 (3.9)                |
| IL-23                          | 31 (3.9)                    | 4 (3.9)                     | 35 (3.9)                |
| Guselkumab                     | 21 (2.7)                    | 1 (1.0)                     | 22 (2.5)                |
| Risankizumab                   | 9 (1.1)                     | 3 (2.9)                     | 12 (1.3)                |
| Tildrakizumab                  | 1 (0.1)                     | 0 (0.0)                     | 1 (0.1)                 |
| No. of previously used biologics [n (%)] |                             |                             |                         | 0.737               |
| 0                              | 510 (64.7)                  | 65 (63.7)                   | 575 (64.6)              |
| 1                              | 159 (20.2)                  | 18 (17.6)                   | 177 (19.9)              |
| 2                              | 59 (7.5)                    | 11 (10.8)                   | 70 (7.9)                |
censored when they discontinued their biologic for a reason other than the reason of interest. Log-rank tests were performed to compare Kaplan–Meier curves between patient groups.

2.3.1 Correcting for Confounders

Baseline characteristics were compared between the two age groups; if baseline variables were different between groups, they were considered as confounders and were incorporated into the Cox regression model. Multiple imputation was used in the case of large amounts of missing data (> 15%). Imputed variables were created and pooled in the model 10 times, and were incorporated in the confounder-corrected model if the variable differed significantly between treatment groups or had a > 10% effect on model outcomes.

2.3.2 Variables Associated with Drug Survival

Additionally, Cox regression analyses with baseline variables were performed with a selection of patients < 65 years of age, and ≥ 65 years of age separately, to investigate associations with drug survival. Baseline variables were tested univariately and incorporated in the multivariable Cox regression model if their association with drug survival was considered clinically meaningful and the \( p \) value was < 0.1.

Backward selection was used to identify relevant variables for the final model.

2.4 Adverse Events Leading to Treatment Discontinuation

All AEs that led to discontinuation of the biologic were collected and classified into categories according to the Medical Dictionary for Regulatory Activities (MedDRA). Patients could have more than one AE simultaneously leading to treatment discontinuation and these were counted as separate AEs in this study. Additionally, all AEs leading to discontinuation were studied to check if they could be classified as serious AEs (SAEs) according to the International Council for Harmonisation (ICH) E6 (R2) Good Clinical Practice Guidelines [12].

2.5 Psoriasis Area and Severity Index (PASI) Analysis

To be able to visualize treatment effectiveness in both age groups, the Psoriasis Area and Severity Index (PASI) scores were analyzed. In the PASI analysis, only TEs with a baseline PASI and at least one follow-up PASI within the first year of treatment were included. Since scheduling visits at the exact time points is not feasible in a clinical setting,
linear interpolation was used to estimate PASIs at the following time points: weeks 6, 12, 26, 39 and 52, and months 18 and 24. Interpolated PASI scores were used to calculate 1-year PASI ≤ 1 and ≤ 5 proportions. Additionally, PASI scores at the time of treatment discontinuation due to ineffectiveness were assessed. Linear regression analyses were performed, with age group as the independent outcome and PASI as the dependent outcome, at 6, 12, 18 and 24 months of treatment. Correction for possible confounders was applied in linear regression analyses.

In patients who discontinued treatment due to ineffectiveness and/or AEs, PASI scores at discontinuation were carried forward using the last observation carried forward (LOCF) method. With this method, PASI scores in the case of early discontinuation are carried forward, which ensures a more conservative approach [13].

2.6 Statistical Analysis

Analyses were performed in SPSS version 25.0 (IBM Corporation, Armonk, NY, USA). A p value < 0.05 was considered significant. Baseline patient and treatment characteristics for the first TE per patient and per biologic were displayed using descriptive statistics [mean ± standard deviation (SD), median (range), N (%)]. Continuous variables were compared between patient groups using one-way analysis of variance (ANOVA) for parametric distributions and Mann–Whitney U tests for non-parametric distributions, respectively. Pearson’s Chi-square test was used for comparison of categorical variables.

3 Results

3.1 Patient Characteristics

We included a total of 890 patients, of whom 102 (11.5%) were 65 years of age or older at the start of biologic therapy compared with 788 (88.5%) patients aged under 65 years. In total, 2013 patient-years were observed: 206 years in patients ≥ 65 years of age and 1807 in patients < 65 years of age. The median follow-up duration was 19 months in patients ≥ 65 years of age versus 22 months in patients < 65 years of age. The median age at the start of biologic treatment was 32.4 years versus 60.5 years in older patients than for younger patients (log-rank test, p = 0.144). Specifically for ineffectiveness, the 5-year drug survival was lower for older patients than for younger patients (44.5% vs. 60.5%; p = 0.006), while the 5-year drug survival with regard to AEs was 82.1% in older patients versus 79.5% in younger patients (p = 0.913). An overview of the reasons for treatment discontinuation and drug survival per age group is given in Table 3.

3.2 Drug Survival

During the first 5 years of treatment, 220 (24.7%) patients discontinued treatment due to ineffectiveness, 90 (10.1%) due to AEs, and 60 (6.7%) for other reasons (mostly due to pregnancy [wish], patient’s own initiative, or unknown reasons). Among those patients who discontinued treatment due to ‘other reasons’, three (0.3%) patients discontinued treatment due to the coronavirus disease 2019 (COVID-19) pandemic, all aged < 65 years. Crude drug survival rates are visualized using Kaplan–Meier curves (Fig. 1). The crude overall 5-year drug survival in older patients was 32.4% versus 42.1% in younger patients (log-rank test, p = 0.006). Specifically for ineffectiveness, the 5-year drug survival was lower for older patients than for younger patients (44.5% vs. 60.5%; p = 0.006), while the 5-year drug survival with regard to AEs was 82.1% in older patients versus 79.5% in younger patients (p = 0.913). An overview of the reasons for treatment discontinuation and drug survival per age group is given in Table 3.

3.2.1 Correcting for Confounders

No extensive confounder correction was performed as age groups had no statistical differences except for the CCI score and hypertension. When corrected for CCI score and hypertension, the hazard ratio (HR) for the variable ‘age group’ was not statistically significant for drug survival due to all discontinuation reasons and drug survival due to AEs. For drug survival due to ineffectiveness, the confounder-corrected HR for age group was 1.497 (95% confidence interval [CI] 1.053–2.129), indicating that older patients had more risk of discontinuing their biologic therapy due to ineffectiveness compared with younger patients.

3.2.2 Variables Associated with Drug Survival

When analysing univariable HRs in the two different age groups separately, sex, BMI, and treatment class were associated with discontinuation due to ineffectiveness, AEs, and ‘all reasons’ in the younger patient group; however, there were no statistically significant associations with discontinuation in older patients. The results of separate univariable and multivariable Cox regression analyses are presented in electronic supplementary Tables 1 and 2.

When implementing imputed data in univariable Cox regression analyses, HRs were pointing in the same direction, showing robustness of the results.
Overall, 115 (12.9%) patients discontinued biologic treatment due to AEs, or AEs and ineffectiveness combined, with a maximum follow-up of years. In older patients, 12 (11.8%) patients discontinued biologic therapy due to AEs compared with 103 (13.1%) younger patients. In total, 155 AEs leading to treatment discontinuation were reported—16 AEs in older patients and 139 AEs in younger patients (see Table 4). Of all AEs, 16 were reported as serious, and these only occurred in younger patients. In both age groups, treatment discontinuation due to AEs was most frequently attributed to infectious causes (5/102 [4.9%] ≥ 65 years and 25/788 [3.2%] < 65 years). Upper respiratory infections/flu-like symptoms were the most frequently reported infections in both age groups.

### 3.3 Adverse Events Leading to Treatment Discontinuation

Data are expressed as n (%) unless otherwise specified

| Comorbidity/medical history | < 65 years of age [n = 788] | ≥ 65 years of age [n = 102] | All patients [n = 890] |
|----------------------------|-----------------------------|-----------------------------|------------------------|
| Myocardial infarctionc     | 30 (3.8)                    | 11 (10.8)                   | 41 (4.6)               |
| Cardiac failurec           | 4 (0.5)                     | 2 (2.0)                     | 6 (0.7)                |
| Peripheral vascular diseasec| 3 (0.4)                     | 8 (7.8)                     | 11 (1.2)               |
| Cerebral vascular diseasec | 17 (2.1)                    | 11 (10.8)                   | 28 (3.1)               |
| Diabetes mellitusc         | 69 (8.7)                    | 31 (30.4)                   | 100 (11.2)             |
| Chronic pulmonary diseasec | 45 (5.7)                    | 11 (10.8)                   | 56 (6.3)               |
| Connective tissue disorderc| 9 (1.1)                     | 1 (1.0)                     | 10 (1.1)               |
| Cancerac                   | 15 (1.9)                    | 14 (13.7)                   | 29 (3.2)               |
| Metastaticc                | 1 (0.1)                     | 0 (0.0)                     | 1 (0.1)                |
| Chronic kidney diseasec    | 9 (1.1)                     | 0 (0.0)                     | 9 (1.0)                |
| Peptic ulcerc              | 13 (1.6)                    | 6 (5.9)                     | 19 (2.1)               |
| Liver diseasec             | 83 (10.5)                   | 16 (15.7)                   | 99 (11.1)              |
| Dementiac                  | 2 (0.2)                     | 3 (2.9)                     | 5 (0.6)                |
| Paraplegiac                | 0 (0.0)                     | 0 (0.0)                     | 0 (0.0)                |
| HIVc                       | 0 (0.0)                     | 0 (0.0)                     | 0 (0.0)                |
| Hypertension               | 157 (19.9)                  | 45 (44.1)                   | 202 (22.7)             |
| Depression                 | 66 (8.4)                    | 7 (6.9)                     | 73 (8.2)               |
| CCIb [median (range)]      | 0 (0–6)                     | 1 (0–7)                     | 0 (0–7)d               |
| 0                          | 598 (75.9)                  | 42 (41.2)                   | 640 (71.9)             |
| 1                          | 140 (17.8)                  | 32 (31.4)                   | 172 (19.3)             |
| 2                          | 31 (3.9)                    | 13 (12.7)                   | 44 (4.9)               |
| ≥ 3                        | 19 (2.4)                    | 15 (14.7)                   | 34 (3.8)               |

CCI Charlson Comorbidity Index, SD standard deviation, ICD-10 International Classification of Diseases, Tenth Revision

a Included all types of cancer other than non-melanoma skin cancer

b The CCI consists of 17 comorbidities and each comorbidity is given a separate weight

c Comorbidities scored in the CCI. In a few cases, specific comorbidities were not scored in the CCI calculation but are depicted here. For specific CCI definitions, see the ICD-10 codes reported by Sundararajan et al. [10]

d A significantly higher CCI was seen in older adults compared with younger patients (p < 0.001)

### 3.4 PASI Analysis

The mean 2-year PASI course split according to age group is shown in Fig. 2. The median baseline PASI was 11.0 (0.0–36.2) in older patients and 11.8 (0.0–45.2) in younger patients. After 1 year of treatment, the median PASI in older and younger patients was 2.8 (0.0–11.5) and 2.6 (0.0–21.7), respectively. The proportion of patients ≥ 65 years of age who reached a PASI score of < 1 after 1 year of treatment was 20.0%, versus 24.6% in patients aged < 65 years. Furthermore, a PASI score of < 5 after 1 year of treatment was reached in 77.1% of patients aged ≥ 65 years, versus 75.4% in patients aged < 65 years. Linear regression analyses on PASI scores showed no statistical differences at 6, 12, 18, and 24 months of treatment, nor after confounder correction for CCI score and hypertension. After applying the LOCF method, similar PASI results were seen (see electronic supplementary text).
4 Discussion

In this prospective real-world psoriasis cohort study, we provide insights into the drug survival, safety, and effectiveness of biologics in older patients with psoriasis, and compare outcomes in younger patients. We set out to reduce the current knowledge gap and improve personalized care for older patients with psoriasis. In total, data of 890 patients were analyzed, of whom 102 were aged ≥ 65 years (11.5%). Overall, the two age groups (< 65 years and ≥ 65 years) were highly comparable regarding patient and disease characteristics. Comorbidities were more common in older patients at the start of biologic treatment, as expected and in line with previous research [14–16]. The overall 5-year drug survival of biologic treatment, including all reasons for treatment discontinuation, was comparable between age groups (≥ 65 years, 32.4%; < 65 years, 42.1%). A significant difference in 5-year drug survival was found only for ineffectiveness as the reason for treatment discontinuation; older patients had a lower ineffectiveness-related drug survival (44.5%) compared with younger patients (60.5%). Furthermore, no difference in 5-year AE-related drug survival between age groups was found (82.1% in older patients vs. 79.5% in younger patients). The number of reported AEs leading to treatment discontinuation in the first 5 years of treatment was low in both groups (≥ 65 years, 11.8%; < 65 years, 13.1%). The PASI course during the first 2 years of treatment was comparable between age groups.

Drug survival is a widely used measure that combines several aspects of treatment modalities (e.g., effectiveness and safety) [17–19]; however, literature on drug survival in older patients with psoriasis is sparse. We found a comparable overall drug survival between the age groups, before and after correction for confounding factors, as also reported for a period of 2 years by Osuna et al. [20]. The crude and confounder-corrected drug survival with regard to ineffectiveness was lower for patients aged ≥ 65 years. Remarkably, PASI scores at discontinuation were slightly lower in older patients, although this was not statistically significant (≥ 65 years, 7.8 [2.6–14.8] versus < 65 years, 9.6 [0.0–34.4]; \( p = 0.347 \)). A possible explanation for the more frequent treatment discontinuation due to ineffectiveness in older patients is the difference in needs or treatment burden between these age groups. Treatment effectiveness in research is often based on disease severity outcome, however individual treatment goals, needs, and preferences can play a significant role in treatment decision making. Although limited literature is available on the needs and treatment goals of older psoriasis patients, some distinct differences have been reported compared with those of younger patients [21, 22]. Older patients found it more important to be free of scaling and redness and to have complete clearance of psoriasis.

Fig 1 Five-year drug survival of older patients compared with younger patients using biologics treatment, split according to discontinuation reasons
lesions than their younger counterparts. Furthermore, mini-
mization of different treatment modalities such as the use of
topical treatment, injections, and tablets or capsules, as well
as reducing hospital visits and laboratory assessments, were
valued significantly higher by older patients [21]. This may
indicate that the treatment burden is experienced as higher,
possibly due to aging-related factors such as comorbidity,
polypharmacy, functional impairment, and low confidence
in psoriasis therapy due to more extensive treatment his-
tory [22–25]. Another possible influential factor on drug
survival differences is treatment adherence; however, evi-
dence regarding the influence of age on treatment adherence
in psoriasis is scarce [26]. One study described a modest
relation between older age and higher levels of treatment
adherence in patients using traditional systemic and biologic
treatment [27].

In general, older patients are more at risk of AEs using
systemic medication due to comorbidity, polypharmacy, and
drug metabolism alterations [28]. We found no difference in
5-year drug survival with regard to AEs between age groups
and no SAEs were reported as the reason for treatment dis-
continuation in older patients. Infections are the most fre-
cently reported AEs in older patients using biologics [14,
29–31]; however, a recent systematic review on systemic
therapies in older patients with psoriasis described no sig-
ificant association with infection occurrence and age [3].
In our study, infections were the most frequently reported
AEs that led to treatment discontinuation in both age groups.
Nevertheless, absolute numbers were comparable and low.

Conflicting evidence has been reported regarding the occur-
rence of neoplasms in older patients using biologics [32]; we
only report one neoplasm leading to treatment discontinua-
tion. Note that we focused only on neoplasms as the reason
for discontinuation, and not on absolute rates of neoplasms
during therapy in both groups.

The PASI course in this study was highly comparable
between age groups, implicating a comparable treatment
response. This trend has previously been described for
adalimumab and etanercept regarding PASI outcomes and
older age [33–35]. A recent systematic review concluded
that effectiveness in older patients is in line with that of
younger patients [3]. Studies evaluating the effectiveness of
IL-17 and IL-23 inhibitors in older patients are scarce and
would be of added value in the future.

Studies regarding older patients using biologics often
have limited sample sizes and focused mainly on separate
biologics. Furthermore, studies describing drug survival in
this population are lacking. Our study is an addition to the
current scarce body of evidence in older patients; however,
more evidence regarding older patients with psoriasis is
being published [20, 36–38]. A strength of this study is
its high external validity, due to its real-world practice
nature, and multicenter, prospective design. When evalu-
ating eligibility for biologic treatment, there is a chance
that patients with high comorbid disease status are more
often excluded. Therefore, the chance of selection bias
regarding comorbidity was assessed. The CCI score of
our older population was compared with that of another

| Table 3 Reasons for treatment discontinuation and drug survival in older patients compared with younger patients |

| Reasons for treatment discontinuation [n (%)] | All patients [n = 890] | < 65 years of age [n = 788] | ≥ 65 years of age [n = 102] | p value* |
|---------------------------------------------|-----------------------|-----------------------------|---------------------------|----------|
| Ineffectiveness                             | 220 (24.7)            | 185 (23.5)                  | 35 (34.3)                 |          |
| Adverse events                              | 90 (10.1)             | 82 (10.4)                   | 8 (7.8)                   |          |
| Ineffectiveness and adverse events          | 25 (2.8)              | 21 (2.7)                    | 4 (3.9)                   |          |
| Other                                       | 60 (6.7)              | 57 (7.2)                    | 3 (2.9)                   |          |
| Lost to follow-up                           | 46 (5.2)              | 42 (5.3)                    | 4 (3.9)                   |          |
| Survival functions (Kaplan–Meier analyses)b |                       |                             |                          |          |
| 1-year (%)                                  |                       |                             |                          |          |
| All reasons                                 | 75.5                  | 75.9                        | 72.0                      | 0.475    |
| Ineffectiveness                             | 84.0                  | 85.0                        | 76.5                      | 0.036    |
| Adverse events                              | 91.0                  | 90.2                        | 92.2                      | 0.613    |
| 5-year (%)                                  |                       |                             |                          |          |
| All reasons                                 | 41.1                  | 42.1                        | 32.4                      | 0.144    |
| Ineffectiveness                             | 58.7                  | 60.5                        | 44.5                      | 0.006    |
| Adverse events                              | 79.7                  | 79.5                        | 82.1                      | 0.913    |

*Log-rank tests were performed to compare Kaplan–Meier curves of patients aged <65 years and ≥65 years
bThe percentage of patients calculated using Kaplan–Meier analysis who are still on drug after 1–5 years of treatment, split according to discontinuation reasons
Drug Survival, Safety and Effectiveness of Biologics in Older Patients with Psoriasis

A limitation of this study is the smaller number of older patients. Furthermore, the 65-year age threshold is arbitrary, as chronological age does not always reflect health status. However, to be able to make a comparison between age groups, this cut-off value was chosen in accordance with existing psoriasis literature [3, 21, 36, 39].

To conclude, in this real-world observational study on biologic treatment in older (≥ 65 years of age) and younger patients, no significant difference in drug survival, safety, and effectiveness was found. The Dutch psoriasis cohort, showing no significant difference and implicating a limited influence of pre-selection.

Table 4  Adverse events leading to treatment discontinuation of biologic therapy in older patients compared with younger patients

| Adverse events (MedDRA classification) | < 65 years of age [n = 103] | ≥ 65 years of age [n = 12] | All patients [n = 115] |
|----------------------------------------|-----------------------------|-----------------------------|-----------------------|
| All AEs                                | 139                         | 16                          | 155                   |
| Cardiac disorders                      | 5 (3.6)                     | 0 (0.0)                     | 5 (3.2)               |
| Endocrine disorders                    | 1 (0.7)                     | 0 (0.0)                     | 1 (0.6)               |
| Eye disorders                          | 2 (1.4)                     | 0 (0.0)                     | 2 (1.3)               |
| Gastrointestinal disorders             | 5 (3.6)                     | 0 (0.0)                     | 5 (3.2)               |
| General disorders and administration site conditions | 18 (12.9)                 | 1 (6.3)                     | 19 (12.3)             |
| Fatigue                                | 6 (4.3)                     | 1 (6.3)                     | 7 (4.5)               |
| Fever                                  | 4 (2.9)                     | 0 (0.0)                     | 4 (2.6)               |
| Oedema                                  | 3 (2.2)                     | 0 (0.0)                     | 3 (1.9)               |
| Malaise                                 | 2 (1.4)                     | 0 (0.0)                     | 2 (1.3)               |
| Other                                   | 3 (2.2)                     | 0 (0.0)                     | 3 (1.9)               |
| Immune system disorders                 | 10 (7.2)                    | 2 (12.5)                    | 12 (7.7)              |
| Infections and infestations            | 25 (18.0)                   | 5 (31.3)                    | 29 (18.7)             |
| Upper respiratory infections/flu-like symptoms | 9 (52.0)                | 2 (12.5)                    | 11 (7.1)              |
| Pneumonia                               | 4 (2.9)                     | 1 (6.3)                     | 4 (2.6)               |
| Skin infections                        | 3 (2.2)                     | 1 (6.3)                     | 4 (2.6)               |
| Urinary tract infections                | 2 (1.4)                     | 0 (0.0)                     | 2 (1.3)               |
| Sepsis                                  | 1 (0.7)                     | 0 (0.0)                     | 1 (0.6)               |
| Other                                   | 6 (4.3)                     | 1 (6.3)                     | 7 (4.5)               |
| Investigations                          | 4 (2.9)                     | 0 (0.0)                     | 4 (2.6)               |
| Musculoskeletal and connective tissue disorders | 12 (8.6)               | 1 (6.3)                     | 13 (8.4)              |
| Neoplasms benign, malignant, and unspecified | 8 (5.8)                  | 1 (6.3)                     | 9 (5.8)               |
| Nervous system disorders                | 13 (9.4)                    | 1 (6.3)                     | 14 (9.0)              |
| Psychiatric disorders                   | 6 (4.3)                     | 1 (6.3)                     | 7 (4.5)               |
| Renal and urinary disorders             | 1 (0.7)                     | 0 (0.0)                     | 1 (0.6)               |
| Respiratory, thoracic, and mediastinal disorders | 8 (5.8)                  | 1 (6.3)                     | 9 (5.8)               |
| Skin and subcutaneous tissue disorders  | 12 (8.6)                    | 1 (6.3)                     | 14 (9.0)              |
| Surgical and medical procedures         | 4 (2.9)                     | 1 (6.3)                     | 5 (3.2)               |
| Vascular disorders                      | 2 (1.4)                     | 0 (0.0)                     | 2 (1.3)               |
| Unknown                                 | 3 (2.2)                     | 1 (6.3)                     | 4 (2.6)               |

Data are expressed as n (%)  
Percentages are calculated using the total amount of AEs in the age groups  
Twenty-seven patients (24 younger patients and 3 older patients) had more than one AE simultaneously, leading to treatment discontinuation  
For the MEDRA classification categories blood and lymphatic system disorders; ear and labyrinth disorders; hepatobiliary disorders; injury, poisoning and procedural complications; metabolism and nutrition disorders; reproductive system; and breast disorders, no AEs that led to treatment discontinuation were reported  
AEs adverse events, MedDRA Medical Dictionary for Regulatory Activities  
*a* Included throat complaints, cough, and pain on the chest after biologic injection  
*b* Included wound infections, infection of eczema, condylomata  
*c* Included latent tuberculosis infection, recurrent infections, toe infection, oral candidiasis, ear infection, gingivitis, fungal infection
(<65 years of age) patients, drug survival regarding discontinuation for all reasons and AEs was high and comparable in older and younger patients. Older patients discontinued biologic treatment more often due to ineffectiveness. This may indicate a difference in needs or treatment burden between age groups, possibly related to aging factors such as extensive comorbid disease status, polypharmacy, or functional impairments. Biologic discontinuation due to AEs did not occur more frequently in older patients and no SAEs leading to treatment discontinuation in older patients were reported. Therefore, treatment of older patients with biologics appears a well-tolerated and effective therapeutic option.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s40266-022-00961-y.

Acknowledgments The authors would like to thank J.M.M. Groenewoud for his guidance in performing the statistical analyses, and L.T.H. Godding for assisting in data management.

Declarations

Conflict of interest E.L.M. ter Haar has carried out investigator-initiated research with financial support from Almirall and has carried out clinical trials for Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen (Radboudumc), The Netherlands. S.E. Thomas carries out clinical trials for Janssen and Novartis. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. M.E. Otero has acted as a consultant for Eli Lilly, P.P.M. van Lümig has received research funding from Wyeth; has carried out clinical trials for Abbott and Janssen-Cilag; has received speaking and consulting fees from Wyeth and Schering-Plough; has received reimbursement for attending a symposium from Schering-Plough and Pfizer; and has attended advisory boards for Abbvie, Leo Pharma, Novartis and UCB. W.P. Arnold has been a consultant, advisory board member, and/or speaker for Abbvie and UCB. S.R.P. Dodemont has attended advisory boards for Abbvie, Janssen and Leo Pharma, and has received a congress fee from Abbvie. M.S. de Bruin-Weller has been a consultant, advisory board member, and/or speaker for Abbvie, Almirall, Arena, Aslan, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme. R.A. Tupker has attended advisory boards for Leo Pharma, UCB Pharma, and Eli Lilly Netherlands. E.M.G.J. de Jong has received research grants for the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands, from AbbVie, BMS, Janssen Pharmaceutica, Leo Pharma, Novartis, and UCB for research on psoriasis; has acted as a consultant and/or paid speaker for, and/or participated in research sponsored by, companies that manufacture drugs used for the treatment of psoriasis or eczema, including AbbVie, Amgen, Almirall, Celgene, Galapagos, Janssen Pharmaceutica, Lilly, Novartis, Leo Pharma, Sanofi and UCB. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. J.M.P.A. van den Reek has carried out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees/attended advisory boards from AbbVie, Janssen, BMS, Almirall, LEO Pharma, and Eli Lilly; and has received reimbursement for attending a symposium from Janssen, Pfizer, Celgene, and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Center Nijmegen, The Netherlands. S.F.K. Lubeek has received research grants for investigator-initiated research by Almirall, and has acted as a consultant and/or paid speaker for Janssen, LEO Pharma, Almirall, Sanofi Genzyme, and Sunpharma. All funding is not personal but goes to the independent research fund of the Department of Dermatology, Radboud University Medical Centre Nijmegen, The Netherlands. M.D. Njoo, P.M. Ossenkoppele, E.N. Kop, J.E.M. Körver, A.L.A. Kuipers, R.J. Lindhout, J.M. Mommers, M.A.M. Benders, M.A. Koetsier, M.B. Visch, and M.M. Kleinpenning have no conflicts of interest to report.

Funding BioCAPTURE was funded by the University Medical Center St Radboud Foundation. This foundation received funding from Pfizer, Janssen, Novartis, LEO Pharma, AbbVie, Almirall, Eli Lilly, and UCB. All decisions regarding the design and execution of this study, data collection, data management, data analysis, interpretation of the data, manuscript preparation, manuscript review, or manuscript approval were made independently from industrial contributions.

Ethics approval Ethical review and approval were waived for this study in consultation with our regional Medical Ethics Committee due to the non-interventional design of the study.

Consent to participate Informed consent was not necessary due to the non-interventional design of this study; however, written informed consent is obtained from every patient included in the study.

Consent for publication Not applicable (see the Consent to participate section).

Data availability statement The data that support the findings of this study are not publicly available as participants of this study did not agree for their data to be shared publicly.

Code availability Not applicable.

Author contributions Conceptualization: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Methodology: ELMtH, SET, JMPAvdR, EMGJdJ and SFKL. Software: ELMtH, SET and JMPAvdR. Validation: JMPAvdR, EMGJdJ and SFKL. Formal analysis: ELMtH, SET

Fig 2 Mean 2-year PASI course + 95% confidence intervals of patients using biologics, comparing age groups. PASI Psoriasis Area and Severity Index
and JMPAvdReek. Investigation: ELMtH and SET. Resources: MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MI AK, MSlDb, BV, WPA, PPvL, MMK. Data curation: MEO, ELMtH and SET. Writing—original draft preparation: ELMtH and SET. Writing—review and editing: JMPAvdR, EMGJdJ and SFKL, MEO, MDN, PMO, ENK, SD, JEMK, ALAK, RJL, RAT, JMM, MAMB, MI AK, MSlDb, BV, WPA, PPvL, MMK. Visualization: ELMtH, SET. Supervision: JMPAvdR, EMGJdJ and SFKL. Project administration: JMPAvdR, EMGJdJ and SFKL. Funding acquisition: MEO, JMPAvdR, EMGJdJ.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Identification, Management of P, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–85. https://doi.org/10.1038/jid.2012.339.

2. Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017;31(2):205–12. https://doi.org/10.1111/jdv.13854.

3. van Winden MEC, van der Schoot LS, van de L’Isle AM, van Vugt LJ, van den Reek J, van de Kerkhof PCM, et al. Effectiveness and safety of systemic therapy for psoriasis in older adults: a systematic review. JAMA Dermatol. 2020;156(11):1229–39. https://doi.org/10.1001/jamadermatol.2020.2311.

4. Schaap MJ, van Winden MEC, Seyger MMB, de Jong EMGJ, Lubeck SFK. Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: a systematic review. J Am Acad Dermatol. 2020;83(2):412–24. https://doi.org/10.1016/j.jaad.2019.07.079.

5. Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Dauden E, Sanchez-Carazo JL, et al. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012;148(4):463–70.

6. Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. Br J Dermatol. 2016;174(3):579–87. https://doi.org/10.1111/bjd.14331.

7. Sandhu VK, Ighani A, Fleming P, Lynde CW. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24(2):174–86. https://doi.org/10.1177/1203475419897578.

8. Grozdev IS, Van Voorhees AS, Gottlieb AB, Hsu S, Lebwohl MG, Bebo BF Jr, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65(3):537–45. https://doi.org/10.1016/j.jaad.2010.05.014.

9. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83. https://doi.org/10.1016/0021-9681(87)90171-8.

10. Sundararajan V, Henderson T, Perry C, Muggivan A, Quan H, Ghali WA. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57(12):1288–94. https://doi.org/10.1016/j.jclinepi.2004.03.012.

11. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med. 2007;4(10):e296. https://doi.org/10.1371/journal.pmed.0040296.

12. European Medicines Agency. ICH E6 (R2) good clinical practice. European Medicines Agency; 2016 [cited 12 Jan 2022].

13. van Lüümg PP, Driessen RJ, Kievit W, Boezeman JB, van de Kerkhof PC, de Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2013;68(1):57–63. https://doi.org/10.1016/j.jaad.2012.05.040.

14. Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari M, Zazzetta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94(3):293–7.

15. Balato N, Patruno C, Napolitano M, Patri A, Ayala F, Scarpa R. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31(4):233–8. https://doi.org/10.1007/s40266-014-0156-6.

16. Phan C, Sigal ML, Esteve E, Reguihai Z, Barthelemy H, Beneton N, et al. Psoriasis in the elderly: epidemiological and clinical aspects, and evaluation of patients with very late onset psoriasis. J Eur Acad Dermatol Venereol. 2016;30(1):78–82. https://doi.org/10.1111/jdv.12850.

17. Bland JM, Altman DG. Survival probabilities (the Kaplan–Meier method). BMJ. 1998;317(7172):1572. https://doi.org/10.1136/bmj.317.7172.1572.

18. Wakkée M, Hollestein LM, Nijsten T. Multivariable analysis. J Invest Dermatol. 2014;134(5):1–5. https://doi.org/10.1038/jid.2014.132.

19. van den Reek J, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, et al. Drug survival studies in dermatology:principles, purposes, and pitfalls. J Invest Dermatol. 2015;135(7):1–5. https://doi.org/10.1038/jid.2015.171.

20. Osuna CG, García SR, Martín JC, Jiménez VG, López FV, Santos-Juanes J. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life (Basel). 2021;11:12. https://doi.org/10.3390/life11121348.

21. van Winden MEC, Ter Haar ELM, Groenewoud JMM, van de Kerkhof PCM, de Jong E, Lubeck SFK. Quality of life, treatment goals, preferences and satisfaction in older adults with psoriasis: a patient survey comparing age groups. Br J Dermatol. 2021;184(4):759–62. https://doi.org/10.1111/bjd.19665.

22. Mau JT, Navarina AA, Sommer R, Anzengruber F, Sorbe C, Mrowietz U, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis—a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33(4):700–8. https://doi.org/10.1111/jdv.15324.

23. Reeve E, Wolff JL, Skehan M, Bayliss ES, Hilmer SN, Boyd CM. Assessment of attitudes toward deprescribing in older medicare beneficiaries in the United States. JAMA Intern Med. 2018;178(12):1673–80. https://doi.org/10.1001/jamainternmed.2018.4720.

24. Sattar S, Alibhai SM, Wildiers H, Puts MT. How to implement a geriatric assessment in your clinical practice. Oncologist.
2014;19(10):1056–68. https://doi.org/10.1634/theoncologist.2014-0180.

25. van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol. 2020;100(14):adv00215. https://doi.org/10.2340/00015555-3569.

26. Thorneloe RJ, Bundy C, Griffiths CE, Ashcroft DM, Cordingly L. Adherence to medication in patients with psoriasis: a systematic literature review. Br J Dermatol. 2013;168(1):20–31. https://doi.org/10.1111/bjd.12039.

27. Hambly R, Kelly A, Gilhooley E, Nic Dhonncha E, Murad A, Hughes R, et al. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment. Br J Dermatol. 2018;178(1):e46–8. https://doi.org/10.1111/bjd.15856.

28. Lavan AH, Gallagher P. Predicting risk of adverse drug reactions in older adults. Ther Adv Drug Saf. 2016;7(1):11–22. https://doi.org/10.1177/2042098615615472.

29. Esposito M, Giunta A, Mazzotta A, Zangrilli A, Babino G, Bavetta M, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology (Basel, Switzerland). 2012;225(4):312–9. https://doi.org/10.1159/000345623.

30. Migliore A, Bizzi E, Laganà B, Altomonte L, Zaccari G, Granata M, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22(2):415–26. https://doi.org/10.1177/039463200902200218.

31. Körber R, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35(2):135–44. https://doi.org/10.1007/s40266-018-0520-z.

32. Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment and safety of secukinumab in elderly subjects with moderate and severe plaque psoriasis. J Am Acad Dermatol. 2017;77(5):845-54.e5. https://doi.org/10.1016/j.jaad.2017.07.013.

33. Menter A, Gordon KB, Leonardi CL, Gu Y, Goldblum OM. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63(3):448–56. https://doi.org/10.1016/j.jaad.2009.09.040.

34. Chimenti MS, Esposito M, Giunta A, Bavetta M, Rinaldi M, Chimenti S, et al. Efficacy and safety of subcutaneous anti-TNF alpha, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: An observational long term study. Annals of the Rheumatic Disease Conference: Annual European Congress of Rheumatology of the European League Against Rheumatism, EULAR. 2012;71.

35. Gordon K, Korman N, Frankel E, Wang H, Jahreis A, Zitnik R, et al. Efficacy of etanercept in an integrated multi-study database of patients with psoriasis. J Am Acad Dermatol. 2006;54(3 Suppl 2):S101–7. https://doi.org/10.1016/j.jaad.2005.11.1088.

36. Phan C, Beneton N, Delaunay J, Reguiai Z, Boulard C, Fougerousse AC, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100(18):adv00316. https://doi.org/10.2340/00015555-3678.

37. Menga M, Napolitano M, Balato N, Monfrequela G, Villani A, Ayala F, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2016;41(5):564–6. https://doi.org/10.1111/ced.12850.

38. Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Menga M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561–7. https://doi.org/10.1111/ced.14979.

39. Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gomez-Garcia FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29(5):858–64. https://doi.org/10.1111/jdv.12688.

Authors and Affiliations

E. L. M. ter Haar1,2,3 · S. E. Thomas1,2 · J. M. P. A. van den Reek1,2 · M. E. Otero1,2 · M. D. Njoo3 · P. M. Ossenkoppele4 · E. N. Kop5 · S. R. P. Dodemont6 · J. E. M. Körver5 · A. L. A. Kuijpers7 · R. J. Lindhout8 · R. A. Tukker9 · J. M. Mommers10 · M. A. M. Berends11 · M. I. A. Koetsier12 · M. S. de Bruin-Weller13 · M. B. Visch14 · W. P. Arnold15 · P. P. M. van Lümm16 · M. M. Kleinpenning17 · S. F. K. Lubeek1,2 · E. M. G. J. de Jong1,18

1 Department of Dermatology, Radboud University Medical Centre (Radboudumc), PO Box 9101, 6500 HB Nijmegen, The Netherlands
2 Radboud Institute for Health Sciences (RIHS), Radboud University Medical Centre (Radboudumc), Nijmegen, The Netherlands
3 Department of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The Netherlands
4 Department of Dermatology, Bernhoven Ziekenhuis, Uden, The Netherlands
5 Department of Dermatology, Catharina Ziekenhuis, Eindhoven, The Netherlands
6 Department of Dermatology, Amphia Ziekenhuis, Breda, The Netherlands
7 Department of Dermatology, Máxima Medisch Centrum, Eindhoven, The Netherlands
8 Department of Dermatology, Jeroen Bosch Ziekenhuis, ’s Hertogenbosch, The Netherlands
9 Department of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The Netherlands
10 Department of Dermatology, Anna Ziekenhuis, Geldrop, The Netherlands
11 Department of Dermatology, Stichting Ziekenhuis, Doetinchem, The Netherlands
12 Department of Dermatology, Gelre Ziekenhuizen, Apeldoorn, The Netherlands

△ Adis
13 Department of Dermatology, Utrecht Medisch Centrum, Utrecht, The Netherlands

14 Department of Dermatology, Ziekenhuis Rijnstate, Arnhem, The Netherlands

15 Department of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands

16 Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands

17 Department of Dermatology, Canisius-Wilhelmina Ziekenhuis, Nijmegen, The Netherlands

18 Radboud University, Nijmegen, The Netherlands